Agenda March 16, 2027: Pre-Conference Workshop & Plenary - PT (Pacific Time, GMT-08:00)
- Nikita Tatwadhia - Scientist, AstraZeneca
- Gregory Keil - Scientific Director, Global Upstream and Cell Line Development, Bristol-Myers Squibb
- Michael Coolbaugh - Head of Advanced Manufacturing Implementation, Sanofi
- Richard Braatz, Ph.D. - Edwin R. Gilliland Professor, Faculty Research Officer, Massachusetts Institute of Technology
- Chad Varner, Ph.D. - Associate Director, Sanofi
Intensified upstream is now common, but fully connected end-to-end processes are still rare. The panel will look at what’s holding the industry back, starting with where the business case is strong and where cost-of-goods and footprint gains disappear, especially for retrofitted or multi-product facilities. Panelists will discuss how higher titers and continuous upstream move the bottleneck to capture, buffer management and viral clearance, and how to keep connected unit operations running at matching rates. They will also cover the real-time control and PAT that end-to-end processing needs, how far the ICH Q13 guidance on continuous manufacturing gets teams with regulators in practice, and the people and supply questions: training operators for weeks-long runs, validating scale-down models, and whether suppliers can support long continuous campaigns.
- Thomas Seewoester, Ph.D. - Vice President, Site Operations, Amgen

